|
|
|
- しょうぶ はぎにわ
- 5 years ago
- Views:
Transcription
1
2
3 ペ ニ シ リ ン耐 性 肺 炎 球 菌 のPBPsとPBP2B遺 NO.11 VOL.42 お,PCR混 合 液AとB(そ ク ス にDNAポ 1227 伝 子 につ いて れ ぞ れの プ ライ マー ミ ッ リ メ ラ ー ゼ 等 を加 え た も の21))用 に,1 菌 株 につ き2本 の マ イ ク ロ チ ュ ー ブ を 準 備 し た チ ュ ー ブ は,Gene Amp PCR System9600-R(日 本 ロ シ ュ )に セ ッ トし,60,20分,続 い て90,10 分 の 溶 菌 操 作 を行 っ た 次 い で,PCR混 合 液 のAと Bと を そ れ ぞ れ の チ ュ ー ブ に 別 々 に5μlず つ加 えた PCRは,①50,30秒,②70,30秒,③94,15 秒 の 条 件 下 で30サ イ ク ル 行 い,反 応 後 の 検 体 は,3% 濃 度 の ア ガ ロ ー ス ゲ ル 板 を用 い て電 気 泳 動 を行 っ て 解 析 した II.結 果 1一 薬 剤 感 受 性 とPCRの Fig.1に は,肺 成 績 の関 係 炎 球 菌3株 に つ い てPCRを 行 い, そ の増 幅 産物 を ゲル 電 気泳 動 した代 表 的 な成 績 を示 す PSSPと 記 し て あ るUB-034株 は,PCGに0.016 μg/ml,mpipcに0.03lμg/mlのmicを 感 受 性 の 上 か らPSSPと ラ ム はlytA遺 DNA分 示 し,薬 剤 判 定 さ れ た 株 で あ る Aカ 伝 子 用 の プ ライ マー で増 幅 され る 子 量 に 相 当 し,Bカ ラ ム はPSSPのPBP2B 検 出 用 プ ラ イ マ ー で増 幅 さ れ る分 子 量 に相 当 した DNAで あ る 以 下,こ の よ う にPCR上 判 定 さ れ る菌 株 をclassSと 中 央 のClassAと でPSSPと 称 す る こ と と した したUB-023株 は,PCGにO.25 μg/ml,mpipcに1.0μg/mlのmicを のPRSPと PCR混 が,分 度 判 定 さ れ た 株 で あ る こ の 菌 株 で は, 合 液Aの み で2本 のDNAが 検 出 され てい る 子 量 の 大 きい 上 の バ ン ドがlytA遺 PBP2BのclassA変 幅 され たDNAの 下,こ 示 し,軽 Fig. 1. Agarose gel electrophotogram of PCR-amplified DNA fragments of the autolysin (lyta) and PBP 2 B (pena) genes. a) penicillin-sensitive Streptococcus pneumoniae strain UB034; b) penicillin-resistant S. pneumoniae strain UB-023; c) penicillin-resistant S. pneumoniae strain UB-008. 伝 子,下 for ly. A and 表現す る contains two sets amplification PBP-2A Tube mers, 分 子 量 に一 致 し た バ ン ドで あ る 以 genes, B contains for of two amplification normal PBP-2B of pri- lyta and respectivesets of genes, of priclass B respec- tively. こと とした 右 側 のUB-008株 A mers, class が 異 を検 出 す る プ ラ イマ ー で 増 の よ う な 菌 株 をclassAのPRSPと Tube は,PCGに4.0μg/ml,MPIPC に8.0μg/mlのMICを 示 し,明 る こ の 菌 株 で はPCR混 当 す るDNA,PCR混 ら か なPRSPで 合 液AでINtA遺 あ 伝 子 に相 め られ る 以 下,こ 分 子 量 に 一 致 し た バ ン ドが 認 の 場 合 に はclassBのPRSPと 成 績 と,β-ラ クタム 系薬感 受性 と 印 で 示 し た4株 で は,変 異 した 検 出 す る た め の プ ラ イ マ ー で はDNAの イ マ ー でDNAが 出用 の プ ラ 増 幅 され た つ ま り,PRSPで あ り 判 定 され て い た こ とで,両 者 の成 の 関 係 をFig.2に 示 す 薬 剤感 受 性成 績 の上 か らの な が ら,classSと PRSPとPSSPの 識 別 は,NCCLSの 績 が 必 ず し も一 致 して い な い菌 株 が み られ た PCGに 対 し て0.1μg/ml以 る い はMPIPCに1.0μg/ml以 PRSPと す る と,こ 勧 告8}に 従 い, 上 のMICを 上 のMICを 示 す 株,あ 示す株 を の 条 件 を 共 に満 た す 菌 株 は 左 上 ま た,PCGに は0.063μg/mlのMICを MPIPCに1.0μg/mlのMICを した が,こ 印 印 で 示 し た1 識別 された し か し な が ら, PBP2Bを で あ っ た そ の うち, はclassBのPRSP, 増 幅 が 認 め られ ず,PSSPのPBP2B検 称 す る こ ととした 各 菌 株 のPCRの で 示 し た10株 株 はclassAのPRSPと 合 液BでPBP2BのclassB 変 異 を検 出 す るDNAの の 図 に 点 線 で 囲 ん だ15株 れ もPRSPで 示 し, 示 し た 株 が1株 あ りな が らclassSと 存在 判定 さ
4 1228 CHEMOTHERAPY NOV Fig. 2. Correlations between the presence of the PBP 2 B (pena) gene and œ normal pena-positive strains by PCR; M: class A pena-positive strains by PCR; A: class B pena-positive strains by PCR. The breakpoints for sensitivity and resistance to penicillin G and oxacillin are based on the recommendations of the NCCLS8).
5 PCG: penicillin G, MPIPC: oxacillin Fig. 3. Fluorogram of the penicillin-binding proteins of penicillin-resistant Streptococcus pneumoniae. Membrane fractions were incubated with [3H]-PCG for 10 min at 32 Ž, sarcosyl solubilized, and electrophoresed.
6
7 Fig. 6. Correlations between the affinity of penicillin-binding proteins and the presence of normal or altered PBP 2 B genes in penicillin-resistant and -sensitive Streptococcus Pneumoniae. (A) reduction of affinitity of [31-1]-PCG for PBP 2 B; (B) normal affinity of [31-1]-PCG for PBP 2 B.0 and normal pena-positive strains by PCR;
8
9 rds. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M 7-A 3. National Committee for Clinical Laboratory Standerds, Villanova, Pa ) Klugman K P: Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3: 171 `196, ) Hakenbeck R, Tarpay M, Tomasz A: Multiple changes of penicillin-binding proteins in penicillin-resistant isolates of Streptococcus Pneumoniae. Antimicrob Agents Chemother 17:364 11) Percheson P B, Bryan L E: Penicillin-binding components of penicillin susceptible and -resistant strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 18: , ) Zighelboim S. Tomasz A: Penicillin-binding proteins of multiply antibiotic-resistant South African strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 17: , ) Hakenbeck R Ellerbrok H Brise T Handwerger S, Tomasz A: Penicillin-binding proteins of penicillin-susceptible and -resistant pneumococci: immunological relatedness of altered proteins and changes in peptides carrying the fi-lactam binding site. Antimicrob Agents Chemother 30: 553 `558, ) Jabes D, Nachman S, Tomasz A: Penicillinbinding protein families: Evidence for the clonal nature of penicillin resistance in chinical isolates of pneumococci. J Infect Dis 159:16-25, ) Hakenbeck R, Briese T, Chalkley L, Ellerbrok H, Kalliokoski R, Latorre C Leinonen M, Martin C: Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae. J Inf Dis 164:313 17) Ubukata K, Yamasita N, Konno M: Occurence of a P-lactam-inducible penisillin-binding prptein in methicillin-resistant staphylococci. Antimicrob Agents Chemother 27: , ) Dowson C G, Hutchison A, Spratt B G: Nucleotide sequence of the penicillin-binding protein 2B gene of Streptococcus pneumoniae strain R 6. Nucleic Acids Res 17: 7518, ) Dowson C G, Hutchison A, Spratt B G: Extensive re-modelling of the transpeptidase domain of penicillin-binding protein 2 B of a penicillin -resistant South African isolate of Streptococcus pneumoniae. Mol Microbiol 3: , ) Garcia P, Garcia K L, Garcia E, Lopez R: Nucleotide sequence and expression of the pneunococcal autolysin gene from its own promoter in Escherichia coli. Gene 43: , ) Ubukata K, Nakagami S, Nitta A, Yamane A, Kawakami S, Sugiura M, Konno M: Rapid detection of the meca gene in methicillinresistant staphylococci by enzymatic detection of polymerase chain reaction products, J Clin Microbiol 30: , ) Markiewicz Z, Tomasz A: Variation in penicillin -binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 27: , ) Martin C, Sibold C, Hakenbeck R: Relatedness of penicillin-binding protein la genes from different clones of penicillin-resistent Streptococcus pneumoniae isolated in South Africa and Spain. EMBO J 11: , ) Laible G, Hakenbeck R, Sicard M A, Joris B, Ghuysen J M: Nucleotide sequences of the pbpx genes encoding the penicillin-binding proteins 2 X from Streptococcus pneumoniae R 6 and a cefotaxime-resistant mutant, C 506. Mol Microbiol 3: , ) Laible G, Spratt B G, Hakenbeck R: Interspecies recombinational events during the evolution of altered PBP 2 x genes in penicillin-resistant clinical isolates of Streptococcus pneumoniae. Mol Microbiol 5: , ) Munoz R, Dowson C G, Daniels M. Coffey T J, Martin C, Hakenbeck R, Spratt B G: Genetics of resistance to third-generation cephalosporins in clinical isolates of Streptococcus pneumoniae. Mol Microbiol 6: , ) Potgieter E, Chalkley L: Reciprocal transfer of penicillin resistance genes between Streptococcus pneumoniae, Streptococcus mitior, and Streptococcus sanguis. J Antimicrob Chemother 28: , ) Dowson C G, Hutchison A, Brannigan J A, George R C, Hansman D, Linares J, Tomasz A, Smith J M, Spratt B G: Horizontal transfer of penicillin-binding protein genes in penicillin -resistant clinical isolates of Streptococcus pne , ) Chalkley L, Schuster C, Potgieter E, Hakenbeck R: Relatedness between Streptococcus pneumoniae ana viridans streptococci: transfer of penicillin resistance determinants and immunological similarlities of penicillin-binding proteins. FEMS Microbiol Lett 90:35-42, ) Dowson C G, Coffey T J, Kell C, Whiley R A: Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in
10 the formation of a law affinity PBP 2 B In S. pneumoniae. Mol Microbiol 9: 635 `643, ) Coffey T J, Dowson C G, Daniels M, Zhou J, Martin C, Spratt B G, Musser J M: Horizontal transfer of multiple penicillin-binding protein genes, and capsular biosynthetic genes, in natural populations of Streptococcus pneumoniae. Mol Microbiol 5: 2255 `2260, ) Munoz R, Musser J M, Crain M, Briles D E, Marton A Parkinson A J Sorenson U, Tomasz A: Geographic distribution of penicillinresistant clones of Streptococcus pneumoniae: charcterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis. Clin Infect Dis 15: , ) Figueiredo A M, Connor J D, Severin A, Vaz Pato M V, Tomasz A: A pneumococcal clinical isolate with high-level resistance to cefotaxime and ceftriaxone. Antimicrob Agents Chemother 36: , ) Bradley J S. Connor J D: Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to bata-lactam antibiotics. Pediatr Infect Dis J 11:871^-873, ) Sloss M M, Barrett F F, Chesney J P, English B K, Hill B C, Tenover F C, Leggiadro R: Cephalosporin treatment failure in penicillinand cephalosporin-resistant Streptococcus Pneumo- 666, ) Kleiman M B, Weinberg G A, Reynolds J K, Allen S a Meningitis with beta-lactam resistant Streptococcus pneumoniae; the need for early repeat lumbar puncture. Pediatr Infect Dis j 12: 782 `784, ) Viladrich P F, Gudiol F, Linares J, Pallares R, Sabate I, Rufi G, Ariza J: Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 35: 2467 `2472, ) Rudolph K M, Parkinson A J. Black C M, Mayer L W: Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol 31: , 1993
11 Mechanisim of resistance in penicillin-resistant clinical isolates of Streptococcus pneumoniae: Analysis of penicillin-binding proteins and the PBP 2 B gene Kimiko Ubukata, Mutumi Sugiura and Masatoshi Konno Department of Clinical Pathology, Teikyo University, School of Medicine, Tokyo, Japan Shigeru Ohnari Department of Pediatris, Saiseikai Hiroshima Hospital, Hiroshima, Japan Akio Yamane Wakunaga Pharmaceutical Co., Ltd., Hiroshima, Japan Susceptibility to fl-lactam antibiotics, affinity of penicillin-binding proteins (PBPs), and the detection of the PBP 2 B gene (pena) by the polymerase chain reaction (PCR) were studied using 30 clinical strains of pneumococci isolated in The following results were obtained: 1) Fifteen of strains were identified as penicillin (PCG) -rsistant strains of pneumococcus (PRSP), with minimum inhibitory concentrations (MIC) of PCGa0.125pg/ml. 2) The MICs of oxacillin, ampicillin, cefotaxime, cefdinir, and imipenem clearly differed in PRSP and PCG-sensitive strains of pneumococcus (PSSP). 3) PCR was performed by preparing three sets of primers for amplification of part of the PBP 2 B gene in order to differentiate between PRSP and PSSP. DNA from 15 strains with a PCG MIC <0.125 jig/m1 was amplified using primers for detection of sensitive strains. The strains for which DNA was amplified with primers for PRSP detection all had MICs a yg/ml. These strains consisted of one class A strain and ten class B strains. However, DNA was amplified by primers for PSSP even in four PRSP strains. 4) In PRSP strains, the affinity of [3H]-PCG for PBP 2 B was reduced, and affinity for PBP-1 A or PBP-1 B was also reduced in many strains. Some PSSP strains showed reduced affinity for PBP-1 A or PBP 1 B, and PBP-2 X newly appeared in some strains. These results suggest that many PRSP in Japan are variable strains with an altered PBP 2 B gene belonging to class B, that there are few class A strains,and that there are PCGresistant strains with changes in the PBP-2 B gene that have not yet beem reported.
Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae
Key words: penicillin insensitive and resistant pneumococcus Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae 小 児
日本 化 学 療 法 学 会 雑 誌 1032 1. Sequences of oligonucleotide primers and their NOV.1995 positions in the lyta gene of pneumoniae used in this study. The nucleotide sequences are numbered on the basis of data
Table 1 Survival rates of infected mice given antibiotic doses producing peak serum a) S. aurcus Smith Challenge dose :7 ~10 (5% mucin) CFU/mouse. LD50: 1 ~103 (5% mucin) CFU/mouse. Table 2 Survival rates
CHEMOTHERAPY
CHEMOTHERAPY VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin CHEMOTHERAPY AUG. 1993 VOL.41 S-2 Laboratory and clinical evaluation of teicoplanin Table 1. Comparative in vitro activity of teicoplanin
Table 1. Antimicrobial drugs using for MIC
Table 1. Antimicrobial drugs using for MIC Table 2. Susceptibilities determined with the VITEK 2 system and agar dilution reference by interpretive eategory for Staphylococcus aureus Table 3. Interpretive
172( 38 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 57 2 Apr. 2002 1 19 6 2002 5 8 4 254 254 (PBP) 90 83 65 142 PBP pbp1a, pbp2x, pbp2b 121 (49%), pbp1a, pbp2x 30 (12%), pbp2x, pbp2b 16 (6%), pbp2x 61 (24%),
日本化学療法学会雑誌第50巻第6号
13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S.
988 CHEMOTHERAPY NOV. 1971
988 CHEMOTHERAPY NOV. 1971 VOL. 19 NO. 8 CHEMOTHERAPY 989 Effect of medium-ph and inoculum size on activity of SB-PC heart infusion agar, mcg/ml Sensitivity distribution of Staphylococci to SB-PC in surgical
Table 1.Quality control of MICs for reference strains Table 2.Antimicrobial activity of gatifloxacin against aerobic bacteria Table 4.Antimicrobial activity of gatifloxacin and other quinolones against
CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle
VOL. 29 NO.8 CHEMOTHERAPY 865 CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Klebsiella pneumoniae GN-69
VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus
MAY 1999 VOL.47 NO.5 Table 1. Susceptibility distribution of ƒà- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus (oxacillin MIC: 4ƒÊg/ ml) FMOX: flomoxef,
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study
CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study VOL. 41 S 1 Table 2. Levels (Đg/ml or Đg/g) of S-1006 in serum, bile, and tissue (gallbladder) after oral administration
Key words : R-plasmid, Urinary tract infection, E. coli Fig. 1. MIC distribution against E. coli isolated from urinary tract (366 strains) and isolation - frequencies of drug-resistant strains Table 1.
THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon
June 2015 THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 189 49 1 : 14 1 2 2 3 1 2 3 2015 4 3 1 : 14 CVA/AMPC 1 : 14 27 CVA/AMPC 1 : 14 88.5% Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St
CHEMOTHERAPY VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant Staphylococcus aureus CHEMOTHERAPY Table
CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote
aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Proteus mirabilis 3.13, Proteus vulgaris 1.56, Citrobacter freundii 0.39,
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood
Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood Fig.1 Distribution of the cases with bacterial meningitis by age and pathogens Chiba
VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )
CHEMOTHERAPY OCT. 1984 Fig. I Chemical structure of CTRX VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains ) CHEMOTHERAPY Fig. 3 Cumulative
The clinical characteristics of Mycoplasma pneumoniae pneumonia in children younger than 6 years old Nobue Takeda1,2),Tomomichi Kurosaki1),Naruhiko Ishiwada2),Yoichi Kohno2) 1)Department of Pediatrics,Chiba
日本化学療法学会雑誌第59巻第6号
P P Streptococcus pneumoniae S. pneumoniae Key words Streptococcus pneumoniae Fig. 1. Capsular swelling reaction of S. pneumoniae type 6B. Cells are stained dark blue using a methylene blue. Capsule is
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin
Key words:group D streptococci,classification,enterococcal infections, Antibiotic susceptibility,vancomycin Table 1 Differentiation of group D streptococcia aderived from R.R.Facklam1,2),K.C.Gross-et al3),and
Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml
CHEMOTHERAPY SEPT. 1992 cefoperazone ceftazidime (CAZ), imipenem (IPM) Staphylococcus sp., Enterococcus (CPZ), faecalis, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae,
VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia
ceftazidime, cefpirome, cefepime, cefoperazone/sulbactam (2: 1), imipenem Staphylococcus aureus oxacillin coagulase negative staphylococci Escherichia coli piperacillin Klebsiellac spp. Citrobacter Pseudomonas
Key words : influenza, nested-pcr, serotype
Key words : influenza, nested-pcr, serotype Table 1 Sequence of PCR primers used to detect HA gene of influenza virus 524 清水 Fig. 1 Detection of PCR product 英明 他 (lstpcr) Table 2 Results method Fig. 2
VOL. 43 NO. 4
VOL. 43 NO. 4 Fig. 1. Frequency of Enterococcus species from complicated UTI, 1988-1992. the number * of Enterococcus species/the number of cases with complicated UTI. Fig. 3 Epidemiologic characteristics
1272 CHEMOTHERAPY MAR. 1975
1272 CHEMOTHERAPY MAR. 1975 VOL. 23 NO. 3 CHEMOTHERAPY 1273 Fig. 2 Minimal inhibitory concentration of aminoglycosides against 50 strains of Klebsiella Fig. 1 Minimal inhibitory concentration of aminoglycosides
VOL.30 NO.12 CHEMOTHERAPY Fig. 1 Effect of temperature on the growth curve of A. calcoaceticus A. calcoaceticits Ac 54 A. calcoacetictts Ac 164 Fig. 2 Effect of medium ph on the growth curve of A. calcoaceticus
Staphylococcus epidermidis Streptococcus pneumoniae Staphylococcus epidermidis Streptococcus pneumontae S. epidermidis Table 1. Summary of the organis
Staphylococcus aureus S. aureus (MRSA) vancomycin (VCM), arbekacin (ABK) Streptococcus pneumoniae cefuzonam (CZON), cefpirome (CPR) S. pneumoniae Enterococcus faecalis ampicillin (ABPC), imipenem (IPM)
Fig. 1 Chemical structure of DL-8280
Fig. 1 Chemical structure of DL-8280 Fig. 2 Susceptibility of cl in ical isolates to DL4280 Fig. 5 Susceptibility of clinical isolates to DL-8280 Fig. 3 Susceptibility of clinical isolates to DL-8280 Fig.
Table 1.Resistance criteria Fig.1.The resistance rates of piperacillin,ceftazidime, cefsulodin,imipenem,aztreonam,gentamicin,tobramycin,amikacin,isepamicin,fosfomycin and ofloxacin against 2,793 strains
49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC lin (ABPC), e
Key words: MIC, agar dilution method, fastidious bacteria, Etes(R) 49619, H. influenzae ATCC49247, C. jejuni ATCC 33252, C. fetus ATCC15296, B. fragilis ATCC 25285, C. soldellii ATCC9714, P. rnagnus ATCC
CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus
VOL. 32 S-4 CHEMOTHERAPY Fig. 1 Chemical structure of sodium cefoperazone Fig. 2 Chemical structure of sodium cefoperazone CHEMOTHERAPY JUN. 1984 Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of BRL 28500 against standard strains of bacteria Fig, 1 Sensitivity distribution of ABPC-resistant E. coli isolated from urinary tract Fig. 2 Sensitivity
CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin
CHEMOTHERAPY CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin CHEMOTHERAPY Fig. 1 MICs of sultamicillin against respiratory pathogenic Branhamella catarrhalis 62 strains, inoculum size 106CFU/m1 Fig.
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile
Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile Key words: temafloxacin, TA-167, Bacteroides fragilis,
b) Gram-negative bacteria Fig. 2 Sensitivity distribution of clinical isolates : E. coli Fig. 3 Sensitivity distribution of clinical isolates : Pseudomonas Fig. 1 Sensitivity distribution of clinical isolates
Fig.1 MICs of penicillins against 24 strains of B. pertussis Fig.2 MICs of cepherns against 24 strains of B. pertussis Fig.3 MICs of macrolides against 24 strains of B. pertussis Fig.4 MICs of nalidixic
180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab
June 2011 THE JAPANESE JOURNAL OF ANTIBIOTICS 64 23 179 ( 63 ) A b cefditoren pivoxil 5 amoxicillin 10 1,2) 1,3) 1) 1) 1) 4) 5) 6) 7) 1) 2) 3) 4) 5) 6) 7) 2011 4 8 2007 5 2009 4 A b GAS cefditoren pivoxil
CHEMOTHERAPY
CHEMOTHERAPY CHEMOTHERAPY Table 1 Antibacterial activity of Sulbactam/CPZ against standard strains MIC mg/ml Inoculum size 106 CFU/ml * Sulbactam/CPZ= 1: 1 ** Concentration of Sulbactam+ CPZ CHEMOTHERAPY
400 46 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 LVFX 100 mg 3 / 7 150 mg 2 / 7 2 2006 2008 9 LVFX PK PD 2009 7 100 mg 1 3 500 mg 1 1 AUC/MIC
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 399 45 2012 11 5 LVFX 500 mg 1 1 20 Chlamydia trachomatis C. trachomatismycoplasma genitalium M. genitalium LVFX 1 500 mg 1 1 7 22 22 C. trachomatis 17
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity
VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity CHEMOTHERAPY MAR. 1989 Mble 1. Allcrgy in parients nduced by penams VOL. 37 NO. 3 Table 2. Allergy in patients induced by
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone
Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone (inoculum size= 106 CFU/ml) (Ĉ-lactamase producer : 2 strains) Fig. 1. Sensitivity distribution of
CHEMOTHERAPY APRIL 1992 VOL. 40 S- 1 Table 1-1. Comparative in vitro activity of meropenem against clinical isolates CNS: coagulase-negative staphylococci CHEMOTHERAPY APRIL 1992 Table 1-2. Comparative
VOL.32 S-9 CHEMOTHERAPY Table 1 Minimum inhibitory concentrations of AC-1370, CPZ and CAZ Table 2 Efficacy of AC-1370 and CPZ against systemic infections in mice *Inoculum size: 106 cells/ml * 95% confidence
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent
Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Enterococcus faecalis Klebsiella pneumoniae, Morganella
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination
Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination Fig. 1 The value of fungal index and D- arabinitol/creatinine. Fungal index was mesured by Endotoxin D and Endospecy
Table 1 Sensitivity distribution of clinical isolates 1. Escherichia coli Inoculum size: 106cells/ml 2. Klebsiella pneumoniae 3. Enterobacter cloacae 4. Serratia marcescens Inoculum size: 106cells/nil
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis
Key words:fatty acid,plant oil,staphylococcus aureus,skin care, atopic dermatitis growth was monitored at 660 nm with a biophotorecorder. Table 1.Relative inhibitory effects of fatty acids,plant oils,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug,
Key words: change serotype, Pseudomonas aeruginosa anti-pseudomonal drug, Table 1 Incidence of changes in serotype of Pseudomonas aeruginosa isolates induced by anti-pseudomonal drugs Number of isolates
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium
THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterobacter spp., Serratia spp., Burkholderia cepacia, Flavobacterium spp., Alcaligenes spp. THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen
Feb. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 1 53 53 Tebipenem pivoxil 1 1, 3 2 2 1 1 Meiji Seika 2 Meiji Seika G 3 Meiji Seika 2015 12 15 Tebipenem pivoxil 10% 2010 4 2013 3 3,547 3,540 3,540 3,331
(ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor (CCL), Cephalothin (CET), Cefazolin (CEZ), Cefotia
Key words: Blood culture, Trend of bacterial isolation, Increasing of staphylococcus, Use of new cephems (ABPC), Carbenicillin (CBPC), Surbenicillin (SBPC), Piperacillin (PIPC), Cephalexin (CEX), Cefaclor
VOL. 17 NO. 7 CHEMOTHERAPY 1305 1) W. BRumFirr et al. : Clinical and laboratory studies with carbenicillin. Lancet 1: 1289~ 1293, 1967 2) E. T. KNUDSEN et al. : A new semisynthetic penicillin active against
CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates
VOL.39 S-1 CHEMOTHERAPY FEB. 1981 Table 1. Activity of cefpirome and others against clinical isolates VOL.39 S-1 CHEMOTHERAPY FEB. 1991 72 M, 55.5 kg 66 F, 53 kg Chronic bronchitis Bronchopneumonia Peak
Fig.1 Chemical structure of BAY o 9867
Fig.1 Chemical structure of BAY o 9867 CHEMOTHERAPY 43 Table 3 Antibacterial spectrum of gram negative bacteria Medium:Heart infusion agar (Nissui) Method:Agar dilution (Streak) CHEMOTHERAPY DEC 1985
CHEMOTHERAPY APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marc
APRIL 1992 Acinetobacter calcoaceticus Staphylococcus aureus, Escherichia coli P. aeruginosa E. eoli, Klebsiella pneumoniae Serratia marcescens P. aeruginosa P. aeruginosa Streptococcus pyogenes Streptococcus
Table 1 Antibacterial spectra of CPM and other antimicrobials against anaerobes Fig. 1 In vitro activity of CPM and other antibiotics against B. fragilis (136 strains) Fig. 2 In vitro activity of CPM and
CHEMOTHERAPY JUNE 1986
VOL. 34 S-3 CHEMOTHERAPY Fig. 1 Structural formula of L-105 CHEMOTHERAPY JUNE 1986 VOL. 34 S-3 CHEMOTHERAPY Table 1 Antibacterial spectra of L-105 against gram negative anaerobic rods Inoculum 106 cells/ml
* Antibiotic resistance: PCG, penicillinase positive; DMPPC, methicillin and other Ĉ-lactams; EM, macrolides and lincomycins; KM, producing a 3'-phosphotransferase; GM, producing a dual enzyme having
VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega
1066 CHEMOTHERAPY MAR. 1975 Table 1 Sensitivity of standard strains VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia
epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia Table 3. Overall clinical efficacy of cefozopran in
Table1MIC of BAY o 9867 against standard strains
Table1MIC of BAY o 9867 against standard strains Fig.2Cumulative and Distribution Curves of MIC (S.aureus 54 strains) 106cfu/ml Fig.3Correlogram of MIC (S.aureus 54 strains) CHEMOTHERAPY 451 Fig.4Cumulative
日本化学療法学会雑誌第61巻第6号
β Moraxella catarrhalis Escherichia coli Citrobacter Klebsiella pneumoniae Enterobacter cloacae Serratia marcescens Proteus Pseudomonas aeruginosa Acinetobacter Bacteroides fragilis β Haemophilus influenzae
Jpn J Electroph 1996; 40: 299
Jpn J Electroph 1996; 40: 299 Jpn J Electroph 図1. ミ ト コ ン ド リ ア3243位 3243位 がGに 変 異 (A G) 変 異 す る と, 制 限 酵 素ApaIに 1996; 40: 301 の 解 析. よ る認 識 サ イ トが 現 れ るの で, 酵 素 で 切 断 され, 137bpサ イ ズ が 検 出 され る. この 測
CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover
VOL.26 S-2 CHEMOTHERAPY Gentamicin (GM), Dibekacin (DKB), Tobramycin Fig. 1 Protein concentration and protein binding rate Table 2 Protein binding rate of PC-904 in serum of healthy adults, and patients
Some Investigations of Urinary Candidiasis Chujiro YAMAMOTO, M. D., Mitsushi MIZUTANI, M. D. and Tokuro SATO, M. D. From the Department of Urology, Ni
Title 尿路 Candida 症に於ける 2,3 の検索 Author(s) 山本, 忠治郎 ; 水谷, 三 ; 佐藤, 徳郎 Citation 泌尿器科紀要 (1961), 7(3): 394-405 Issue Date 1961-03 URL http://hdl.handle.net/2433/112109 Right Type Departmental Bulletin Paper Textversion
日本化学療法学会雑誌第64巻第4号
β β Moraxella catarrhalisescherichia colicitrobacter Klebsiella pneumoniaeenterobacter cloacaeserratia marcescens Proteus Providencia Pseudomonas aeruginosaacinetobacter Bacteroides fragilis β β E. colik.
VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human
CHEMOTHERAPY Fig. 1 Chemical structure of carumonam Disodium(+)-(Z)-CCE1-(2-amino-4-thiazoly1)-2-[[(2S, -(carbamoyloxymethyl)-4-oxo-1-sulfonato-3-azetidinyll -2-oxoethylidene] amino] oxy] acetate 3S)-2
CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX
Fig. 1 Chemical structure of CXM-AX NOV. 1986 Fig. 2 Sensitivity distribution of clinical isolates organisms (106 cells/ml) a Smurcus 27 strains d) P.m irabilis 15 strains b Ecol i 27 strains 111.morganii
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin
VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin 1380 CHEMOTHERAPY MAR. 1975 Table 2 Susceptibility of isolated Pseudomonas aeruginosa to various antibiotics
日本化学療法学会雑誌第53巻第S-3号
moxifloxacin in vitro moxifloxacin in vitro 17 9 6 17 11 21 moxifloxacinmflx in vitro cefdinir CFDNclavulanic acidamoxicillincvaampcclarithromycincamclindamycincldm levofloxacinlvfx 1MFLX Clostridium clostridiiformeclostridium
2 2 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 Feb. 2012 CLSI M100-S17benzylpenicillin PCG MIC 0.05 g/ml S. pneumoniae penicillin-susceptible S. pneumon
Feb. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 1 1 1 2008 2009 2011 10 25 2008 6 2009 4 Streptococcus pneumoniae 377 penicillin-binding protein: PBP 2004 S. pneumoniae 160 2 2 THE JAPANESE JOURNAL OF
Key words: Staphylococcus epidermidis, biotype, slim production, fi-lactamase test, plasmid analysis
Key words: Staphylococcus epidermidis, biotype, slim production, fi-lactamase test, plasmid analysis 臨 床 材 料 由 来 のS.epidermidisに し た.血 液 由 来株 以 外 の 臨 床 材 料 由来 株 は と くに 生 化 学 的 性 状(生 APIス タ フ(ア ス カ 純 薬)とVITEK(マ
Key words: yeast, Etest(R), microdilution method, MIC Table 1 MICs of quality control strains The data shown are the range of MIC performed in triplicate Table 2 Renge of MICs, MIC50s and MIC90s for 81
The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi
The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursing Professionals for Diabetic Outpatients Not Using
CHEMOTHERAPY APRIL 1992 Table 2. Concentration of meropenem in human prostatic fluid Table 1. Background of 21 chronic complicated UTI cases * NB + BPH, NB + Kidney tumor, NB + Kidney tuberculosis Table
2) Goetz, A., Tsuneishi, N.: Application of molecular filter membranes to the bacteriological analysis of water, J. Am. Water Works Assn., 43 (12): 943-969,1951. 3) Clark, H.F. et al.: The membrane filter
43 Acontum apoiense 17 19581147 1988 17 2001 A4 A4 H17. 4.20. 3. 1012 131421 IT 50 10,340 11,521 2 3 8 9 9 10 10 15 19 20 21 21 1617 22 23 1904 1928 1940 Nature MRSA MRCNS VREVRSA PRSP BRNAR MDRP ESBL)MBL
1 LINE31.1 28.010.3 37.4 24.9 10 9 8 7 6 5 3 1 88.9 77.7 66.7 64.1 62.9 61.3 56.5 56.4 42.2 31.7 28.0 31.1 31.5 30.4 28.6 20.7 16.8 15.9 13.5 10.3 7.9
2014 SNSFacebook Twitter SNS 2014 4 52.8 20 ~ 1 ~ 1 LINE31.1 28.010.3 37.4 24.9 10 9 8 7 6 5 3 1 88.9 77.7 66.7 64.1 62.9 61.3 56.5 56.4 42.2 31.7 28.0 31.1 31.5 30.4 28.6 20.7 16.8 15.9 13.5 10.3 7.9
26 蛋白質 図4細 核酸 胞 壁 の ペ プ チ 酵素 Vol 45No 8 2000 ドグ リ カ ン 合 成 経 路 L Ala L一 ア ラ ミ ン D一Glu D一 ノ マ ー PBP 5 グ ル タ ミ ン 酸 L Lys L一 リ シ ン D Ala D一 ア ラ ニ ン TGlト ラ ン ス グ リ コ シ ラ ー ゼ MM ム レイ ンモ ペ ニ シ リン 結 合 蛋 白 質 メチ
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
22 610407487 ロ ペ ミ ッ ク 小 児 用 0. 0 5 % 2319001C1072 23 610412059 ゲ シ ン L 錠 5 0 m g 2478001G1046 24 610412105 ソ レ ル モ ン S R カ プ セ ル 3 7. 5 m g 1147002N1
お 知 ら せ ( 薬 ) 0 0 5 平 成 2 0 年 8 月 2 9 日 医 薬 品 マ ス タ ー の 改 定 に つ い て 今 般 下 記 の と お り 医 薬 品 マ ス タ ー を 改 定 し ま し た の で お 知 ら せ し ま す 記 次 の 医 薬 品 に つ い て は 平 成 2 0 年 3 月 5 日 付 け 厚 生 労 働 省 告 示 第 7 2 号 に 基 づ
_02三浦.indd
36, 7-11, 2016 IPD PCV 5 3 80% 1 invasive pneumococcal disease ; IPD 2010 7 PCV7 2013 13 PCV13 IPD IPD 2,3 2015 1 2015 12 5 1 IPD 2015 1 12 IPD 5 IPD 1 4 2 5 http://pneumocatch.jp/ 5 Statens Serum Institut
CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz
VOL.33 S-5 CHEMOTHERAPY 381 Fig. 1 Chemical structure of HAPA-B Chemical name 1-N-[(2S)-3-Amino-2-hydroxypropiony1]-4-0-(6-amino- 6-deoxy-a-D-glucopyranosyl)-6-013-deoxy-4-C-methyl- 3-(methylamino)-ƒÀ-L-arabinopyranosyl]-2-deoxystreptamine
Table 1 Detection bacterial strains used in this study *1; Methicillin resistant strains(mrsa)
Key words: PCR, ribosomal RNA, bacterial contamination Table 1 Detection bacterial strains used in this study *1; Methicillin resistant strains(mrsa) PCR法 Fig. 1 Agarose gel ribosomal DNA Amplification
CHEMOTHERAPY SEPT. 1970
CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY CHEMOTHERAPY SEPT. 1970 VOL. 18 NO. 5 CHEMOTHERAPY 691 692 CHEMOTHERAPY SEPT. 1970 VOL. 78 NO. CHEMOTHERAPY 5 写 真1 第1病 693 写 真4 日 In vitroの しCEZの 第22病
1) i) Barber, M. et al.: Brit. Med J, 2, 565, 19'49. ii) Barber, M.F.G. J. Hayhoe and J. E. M. Whithead: Lancet, 1120 `1125, 1949.-2) Bergey: Bergey's Manual of Determinative Bacteriology 7 th Ed: (1958).-3)
感染症学雑誌第77巻第8号
1 2 µ Streptococcus pneumoniae µ S. pneumoniae µ S. pneumoniae pbp β β pbp1a pbp2x pbp2b pbp mefe ermb pbp pbp1a pbp2x pbp2b pbp pbp pbp pbp 2x pbp1a pbp2x pbp 2b mefe ermb pbp β pbp2x β β β µ µ pbp3 µ
VOL.42 S-1
CHEMOTHERAPY APR. 1994 VOL.42 S-1 CHEMOTHERAPY APR. 1994 Table 1. Criteria for evaluation of clinical efficacy by the Japanese Society of Oral and Maxillo-Facial Surgeons Grades of symptoms and numerical
dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc), cephaloridine (CER), nalidixic acid(na
Key words: Shigella, Bacterial resistance against entibiotics. Distribution of R factors dihydrostreptomycin(sm), sulfanilamide(sa), kanamycin(km), paromomycin(prm), fradiomycin(frm), ampicillin(apc),
CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin
CHEMOTHERAPY Fig. 2 Urinary excretion of mezlocillin Fig. 1 Blood levels of mezlocillin CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels
Key words : arbitrarily primed PCR, Salmonella enterica serovar Enteritidis, plasmid DNA profile, antimicrobial susceptibility, phage type
Key words : arbitrarily primed PCR, Salmonella enterica serovar Enteritidis, plasmid profile, antimicrobial susceptibility, phage type Table 1 Strains of S. Enteritidis Table 2 Primers used in the AP-PCR
Table 1 Bacteriae to be tested (1) Gram positive cocci Coagulase positive staphylococcus Coagulase negative staphylococcus Streptococcus pneumoniae Gr
Chlamydia trachomatis Key words: chlamydial antigen, ELISA, bacteria, cross reaction, respiratory infection C. trachomatis Branhamella catarrhalis C. trachomatis C. trachomatis Chlamydia trachomatis (C.
Table 1.Concentration of gatifloxacin (Middle-ear) Table 2.Concentration of gatifloxacin (Paranasal sinuses) Table 3.Concentration of gatifloxacin (Tonsil) Table 4.No.of patients studied Table 5.Background
366 12 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec. 2012 1 8 DNA 2,3 16 12 20 171 2008 12 2010 11 2 3,558 4.44% 1.65% 1.17% 90% 9 Escherichia coli -
Dec. 2012 THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 365 11 sita oxacin 1 1 1 1 1 1 2 2 3 3 1 1 1 2 3 2012 9 14 sita oxacin STFX 50 mg 10% 2008 1 2008 12 2010 11 2 STFX 1,452 91.4% 1,235/1,351 95.9% 466/486
VOL. 34 S-2 CHEMOTH8RAPY 913
VOL. 34 S-2 CHEMOTH8RAPY 913 914 CHEMOTHERAPY APR. 1986 Fig. 1 Chemical structure of T-2588 and T-2525 T- 2588 pivaloyloxymethyl (+ )- (6 R, 7 R)-7-[(Z)-2- (2-amino- 4-thiazolyl)-2-methox yiminoacetamido]-3-[(
CHEMOTHERAPY NOV Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aur
CHEMOTHERAPY NOV. 1985 Fig. 1 Imipenem (MK-0787) Enterobacter cloacae Enterobacter aero Morganella morganii Pseudo- Acinet ob acter Staphylococcus aureus Streptococcus pyogenes Escherichia coli Klebsiella
01-a-‹ä‘㑼‰v-4.03
THE JAPANESE JOURNAL OF ANTIBIOTICS 57 5 425( 1 ) Telithromycin 7 20 PROTEKT (Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin) Telithromycin (TEL) TEL ermb mefa
Oct THE JAPANESE JOURNAL OF ANTIBIOTICS Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, taz
Oct. 2016 THE JAPANESE JOURNAL OF ANTIBIOTICS 69 5 327 27 2013 2014 2016 7 5 2013 2014 Pseudomonas aeruginosa 186 P. aeruginosa piperacillin PIPC, tazobactam/piperacillin TAZ/PIPC, ceftazidime CAZ, cefepime
coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F
VOL.43 S-1 coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, Flavobacter- Table 1. Concentration of grepafloxacin